XOMA Royalty (XOMA) Change in Receivables (2010 - 2026)
XOMA Royalty (XOMA) reported Change in Receivables of -$325000.0 for Q1 2026, down 108.77% on a YoY basis from $3.7 million in Q1 2025, and down 126.23% sequentially from $1.2 million in Q4 2025.
XOMA Royalty (XOMA) Change in Receivables (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Change in Receivables data on file, last reported at -$325000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables fell 108.77% year-over-year to -$325000.0; the trailing twelve-month figure through Mar 2026 stood at $892000.0 (down 83.9% YoY), and the FY2025 full-year result was $2.4 million, up 190.54% from the prior year.
- Change in Receivables fell to -$325000.0 in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $3.7 million in Q1 2025 to a low of -$3.7 million in Q2 2025.
- A 5-year average of $157625.0 and a median of $8000.0 in 2022 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables soared 6506.67% in 2023 and slumped 20120.0% in 2024, its largest moves.
- Tracing XOMA's Change in Receivables over 5 years: stood at -$15000.0 in 2022, then soared by 6506.67% to $961000.0 in 2023, then declined by 17.38% to $794000.0 in 2024, then jumped by 56.05% to $1.2 million in 2025, then plunged by 126.23% to -$325000.0 in 2026.
- Business Quant data shows XOMA's Change in Receivables at -$325000.0 in Q1 2026, $1.2 million in Q4 2025, and -$3.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | -325,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -325,000.00 |
| Mar 31, 2026 | -325,000.00 |
| Dec 31, 2025 | 1.24 Mn |
| Dec 31, 2025 | 1.24 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Dec 31, 2024 | 794,000.00 |
| Dec 31, 2024 | 794,000.00 |
| Sep 30, 2024 | 519,000.00 |
| Sep 30, 2024 | 519,000.00 |
| Jun 30, 2024 | 523,000.00 |
| Jun 30, 2024 | 523,000.00 |
| Mar 31, 2024 | -1.00 Mn |
| Mar 31, 2024 | -1.00 Mn |
| Dec 31, 2023 | 961,000.00 |
| Dec 31, 2023 | 961,000.00 |
| Sep 30, 2023 | -858,000.00 |
| Sep 30, 2023 | -858,000.00 |